149 related articles for article (PubMed ID: 29175444)
1. 17β-estradiol suppresses carboxylesterases by activating c-Jun/AP-1 pathway in primary human and mouse hepatocytes.
Wu L; Hafiz MZ; Guan Y; He S; Xiong J; Liu W; Yan B; Li X; Yang J
Eur J Pharmacol; 2018 Jan; 819():98-107. PubMed ID: 29175444
[TBL] [Abstract][Full Text] [Related]
2. Involvement of pregnane X receptor in the suppression of carboxylesterases by metformin in vivo and in vitro, mediated by the activation of AMPK and JNK signaling pathway.
Shan E; Zhu Z; He S; Chu D; Ge D; Zhan Y; Liu W; Yang J; Xiong J
Eur J Pharm Sci; 2017 May; 102():14-23. PubMed ID: 28238946
[TBL] [Abstract][Full Text] [Related]
3. Decreased carboxylesterases expression and hydrolytic activity in type 2 diabetic mice through Akt/mTOR/HIF-1α/Stra13 pathway.
Chen R; Wang Y; Ning R; Hu J; Liu W; Xiong J; Wu L; Liu J; Hu G; Yang J
Xenobiotica; 2015; 45(9):782-93. PubMed ID: 25801056
[TBL] [Abstract][Full Text] [Related]
4. Presence and inter-individual variability of carboxylesterases (CES1 and CES2) in human lung.
Gabriele M; Puccini P; Lucchi M; Vizziello A; Gervasi PG; Longo V
Biochem Pharmacol; 2018 Apr; 150():64-71. PubMed ID: 29407485
[TBL] [Abstract][Full Text] [Related]
5. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.
Merali Z; Ross S; Paré G
Drug Metabol Drug Interact; 2014; 29(3):143-51. PubMed ID: 24988246
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2.
Yang J; Shi D; Yang D; Song X; Yan B
Mol Pharmacol; 2007 Sep; 72(3):686-94. PubMed ID: 17537833
[TBL] [Abstract][Full Text] [Related]
7. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
[TBL] [Abstract][Full Text] [Related]
8. Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver.
Zhu HJ; Appel DI; Jiang Y; Markowitz JS
Drug Metab Dispos; 2009 Sep; 37(9):1819-25. PubMed ID: 19487248
[TBL] [Abstract][Full Text] [Related]
9. Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity.
Wong CC; Cheng KW; Xie G; Zhou D; Zhu CH; Constantinides PP; Rigas B
J Pharmacol Exp Ther; 2012 Feb; 340(2):422-32. PubMed ID: 22085648
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the c-Jun N-terminal kinase pathway by 17beta-estradiol can preserve human islet functional mass from proinflammatory cytokine-induced destruction.
Eckhoff DE; Smyth CA; Eckstein C; Bilbao G; Young CJ; Thompson JA; Contreras JL
Surgery; 2003 Aug; 134(2):169-79. PubMed ID: 12947315
[TBL] [Abstract][Full Text] [Related]
11. Lipopolysaccharide down-regulates carbolesterases 1 and 2 and reduces hydrolysis activity in vitro and in vivo via p38MAPK-NF-κB pathway.
Mao Z; Li Y; Peng Y; Luan X; Gui H; Feng X; Hu G; Shen J; Yan B; Yang J
Toxicol Lett; 2011 Mar; 201(3):213-20. PubMed ID: 21237253
[TBL] [Abstract][Full Text] [Related]
12. Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver.
Sato Y; Miyashita A; Iwatsubo T; Usui T
Drug Metab Dispos; 2012 May; 40(5):902-6. PubMed ID: 22293119
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of carboxylesterases 1 and 2 plays an important role in prodrug metabolism in immunological liver injury rats.
Zhang C; Xu Y; Gao P; Lu J; Li X; Liu D
Int Immunopharmacol; 2015 Feb; 24(2):153-158. PubMed ID: 25499727
[TBL] [Abstract][Full Text] [Related]
14. Age-related inducibility of carboxylesterases by the antiepileptic agent phenobarbital and implications in drug metabolism and lipid accumulation.
Xiao D; Chen YT; Yang D; Yan B
Biochem Pharmacol; 2012 Jul; 84(2):232-9. PubMed ID: 22513142
[TBL] [Abstract][Full Text] [Related]
15. Fluoxetine reduces CES1, CES2, and CYP3A4 expression through decreasing PXR and increasing DEC1 in HepG2 cells.
Shang W; Liu J; Chen R; Ning R; Xiong J; Liu W; Mao Z; Hu G; Yang J
Xenobiotica; 2016; 46(5):393-405. PubMed ID: 26340669
[TBL] [Abstract][Full Text] [Related]
16. Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2.
Wang J; Williams ET; Bourgea J; Wong YN; Patten CJ
Drug Metab Dispos; 2011 Aug; 39(8):1329-33. PubMed ID: 21540359
[TBL] [Abstract][Full Text] [Related]
17. Insulin transcriptionally down-regulates carboxylesterases through pregnane X receptor in an Akt-dependent manner.
Yang X; Zhang X; Liu Y; Xi T; Xiong J
Toxicology; 2019 Jun; 422():60-68. PubMed ID: 31005591
[TBL] [Abstract][Full Text] [Related]
18. Gambogic acid potentiates clopidogrel-induced apoptosis and attenuates irinotecan-induced apoptosis through down-regulating human carboxylesterase 1 and -2.
Ning R; Wang XP; Zhan YR; Qi Q; Huang XF; Hu G; Guo QL; Liu W; Yang J
Xenobiotica; 2016 Sep; 46(9):816-24. PubMed ID: 26750665
[TBL] [Abstract][Full Text] [Related]
19. Effects of alcohol on human carboxylesterase drug metabolism.
Parker RB; Hu ZY; Meibohm B; Laizure SC
Clin Pharmacokinet; 2015 Jun; 54(6):627-38. PubMed ID: 25511794
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the inhibition of human carboxylesterases (CESs) by the active ingredients from
Fu Q; Yang K; Hu RX; Du Z; Hu CM; Zhang X
Xenobiotica; 2019 Nov; 49(11):1260-1268. PubMed ID: 30486721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
